3646 results for «538»
3646 results
TAVI for aortic regurgitation
20 May 2026 – From EuroPCR 2026
This session highlights innovative transcatheter aortic valve implantation (TAVI) approaches for treating aortic regurgitation, focusing on off-label uses and complex cases. It features high-risk patient interventions, including nonagenarian patients, and strategies to manage severe non-calcific native valve regurgitation with balloon-expandable valves.
When transfemoral is not an option: is TAVI still possible?
20 May 2026 – From EuroPCR 2026
This session explores alternative access strategies for Transcatheter Aortic Valve Implantation (TAVI) when the transfemoral route is not feasible. It covers complex scenarios including transcaval TAVI complications, transaxillary approaches, management of extra-large annuli with peripheral artery disease, and innovative transcarotid valve-in-valve procedures.
Imaging and physiology-guided DCB strategy
20 May 2026 – From EuroPCR 2026
Delve into advanced imaging and physiology-guided drug-coated balloon (DCB) strategies for complex coronary lesions. This session presents integrated approaches combining morphology and physiology, OCT guidance, and real-world cases highlighting DCB use in multivessel disease and calcified lesions.
Imaging and physiology integration to guided PCI
20 May 2026 – From EuroPCR 2026
Discover the integration of imaging and physiological assessment in guiding percutaneous coronary intervention (PCI). This session highlights the use of multimodality diagnostics, including invasive and non-invasive techniques, to improve planning, strategy, and management of complex coronary lesions.
The JenaValve Trilogy™ heart valve system in high surgical risk patients with symptomatic, severe aortic regurgitation: The ALIGN AR Trial
25 Oct 2023
Nicola Ryan provides her take on the ALIGN AR trial which was presented by Vinod H. Thourani at TCT Congress 2023. The Align AR trial is a prospective single-arm investigation device exemption study assessing the safety and efficacy of the Trilogy transcatheter heart valve system in patients with...
Author
The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation
01 Sep 2025
Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.
Author
![The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]](https://www.pcronline.com/var/pcrov3/storage/images/pcronline/news/congress-coverages/esc/2025/aquatic-trial-quitting-versus-using-aspirin-therapy-patients-stabilized-cad-stenting-long-term-oral-anticoagulation/27448089-9-eng-GB/The-AQUATIC-trial-Assessment-of-quitting-versus-using-aspirin-therapy-in-patients-with-stabilized-coronary-artery-disease-after-stenting-who-requi_image_responsive_6.jpg)